SCHEMBL7356540

SCHEMBL7356540

CCC[C@@H](O)[C@@H](CCCc1ccccc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 1/20 0.47
PPARG P37231 5/20 0.44
PTGES O14684 4/20 0.44
ALOX5 P09917 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
HDAC3 O15379 1/20 0.43
MAPK1 P28482 1/20 0.43
ADRA1A P35348 1/20 0.43
HDAC4 P56524 1/20 0.43
SLC6A3 Q01959 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
MMP3 P08254 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17979633 1.00 GRIK1 (0.47) GRIK1PPARGPTGESALOX5SMN1; SMN2
SCHEMBL17979645 0.95 TRPA1 (0.48) GRIK1PPARGPTGESALOX5SMN1; SMN2
SCHEMBL18022912 0.90 CSNK1E (0.54) PPARGPTGESALOX5MMP3TRPA1
SCHEMBL17979632 0.85 CYP1A2 (0.52) PPARGHDAC1HDAC8PPARASIGMAR1
SCHEMBL17979642 0.84 LDHA (0.48) ALOX5SMN1; SMN2MAPK1KMT2A
SCHEMBL28014450 0.83 GRIK1 (0.57) GRIK1PPARGSMN1; SMN2HDAC3MAPK1
SCHEMBL17979638 0.82 RARB (0.55) MMP3KMT2A
SCHEMBL24252168 0.82 GRIK1 (0.50) GRIK1PPARGSMN1; SMN2HDAC3MAPK1
SCHEMBL17510916 0.82 GRIK1 (0.50) GRIK1PPARGSMN1; SMN2HDAC3MAPK1
SCHEMBL7407976 0.82 SLC1A3 (0.54) HDAC3HDAC4HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6329400-B1 INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS GLAXO WELLCOME INC. 2001-12-11 US disclosed
WO-2000012082-A1 FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS GLAXO GROUP LIMITED (GB) 2000-03-09 WO disclosed